Barinthus Biotherapeutics’ (BRNS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Barinthus Biotherapeutics (NASDAQ:BRNS) in a research note issued to investors on Tuesday morning,Benzinga reports. The brokerage currently has a $5.00 price objective on the stock.

Separately, Alliance Global Partners cut their price objective on shares of Barinthus Biotherapeutics from $11.00 to $9.50 and set a “buy” rating for the company in a research report on Tuesday, August 13th.

Barinthus Biotherapeutics Stock Down 9.5 %

NASDAQ BRNS opened at $0.89 on Tuesday. The business’s 50-day moving average price is $1.26 and its 200 day moving average price is $1.49. The firm has a market cap of $35.38 million, a P/E ratio of -0.60 and a beta of -0.59. Barinthus Biotherapeutics has a 52-week low of $0.81 and a 52-week high of $4.16.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its earnings results on Wednesday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.23. The company had revenue of $14.97 million during the quarter. During the same quarter in the prior year, the firm posted ($0.37) earnings per share. As a group, analysts anticipate that Barinthus Biotherapeutics will post -1.52 earnings per share for the current year.

Institutional Trading of Barinthus Biotherapeutics

Hedge funds have recently modified their holdings of the business. Catalina Capital Group LLC purchased a new position in Barinthus Biotherapeutics in the second quarter worth $25,000. Ipswich Investment Management Co. Inc. acquired a new position in shares of Barinthus Biotherapeutics during the 2nd quarter worth $32,000. BlueCrest Capital Management Ltd purchased a new position in shares of Barinthus Biotherapeutics in the 1st quarter valued at about $1,292,000. DC Funds LP purchased a new position in shares of Barinthus Biotherapeutics in the 1st quarter valued at about $1,528,000. Finally, Alphabet Inc. purchased a new stake in Barinthus Biotherapeutics during the second quarter worth about $2,119,000. 25.20% of the stock is owned by institutional investors and hedge funds.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.